A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2019
Price : $35 *
At a glance
- Drugs Daclatasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms COMMIT
- Sponsors Janssen-Cilag
- 18 Jan 2018 Results of pooled post-hoc analysis assessing impact of pharmacokinetic interaction between simeprevir and concomitant medications by using data from nine studies (SONET, OPTIMIST-1, OPTIMIST-2, COMMIT, GALAXY, OSIRIS, IMPACT, PLUTO and SATURN) published in the British Journal of Clinical Pharmacology.
- 04 May 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Interim results (n=106) presented at The International Liver Congress™ 2016